Regulatory file
MOTS-c legal status in the cited FDA record
The FDA entries in this collection end before a scheduled advisory meeting. Their dates limit the legal answer they can supply.
FDA documents verified May 29, 2026
The MOTS-c peptide had no FDA-approved use, formulation or dose in the cited compounding record. It was neither a dietary supplement nor an approved over-the-counter medicine. Material described for laboratory research carried that research status.
The FDA references were verified May 29, 2026. The advisory committee calendar scheduled discussion of MOTS-c for July 23-24, 2026. The sources here contain the meeting notice and the pre-meeting position; they contain no subsequent decision. This page therefore cannot certify the position after that meeting.
My threshold for an access announcement is an actual decision, rather than a calendar entry. A dated legal inventory has to stop where its documents stop.
503A bulk-substance eligibility
A bulk drug substance is the active starting ingredient a pharmacy uses to compound a medicine. The FDA explanation of section 503A sets out routes by which an ingredient can qualify: an applicable official compendial standard, its presence in an FDA-approved drug, or inclusion on the 503A Bulks List.
None of those routes applied to MOTS-c in the cited pre-meeting record. It lacked approval and a place on the one-patient compounding list. Ordinary use through that pathway was unavailable while that record stood. A prescription naming a patient also has to meet the ingredient rules.
The same FDA material distinguishes state-licensed, patient-specific pharmacy compounding under 503A from FDA-registered outsourcing facilities operating under the separate 503B requirements. The latter can supply certain larger batches for offices and hospitals under their own rules. The distinction concerns legal requirements for preparation; it supplies no human safety finding for MOTS-c.
MOTS-c acetate and the advisory meeting
The Pharmacy Compounding Advisory Committee notice listed MOTS-c and MOTS-c acetate for consideration for the 503A Bulks List. Acetate identifies a chemical form of the substance. The notice supplies no conclusion about a safety difference between those forms.
Advisers provide recommendations; FDA makes the final regulatory decisions through its applicable process. The scheduled discussion therefore left eligibility unresolved. The cited record also did not place MOTS-c in Category 2, the safety-risk category described in the FDA bulk-substances materials. Its review was unfinished, and its absence from that category supplied no finding of safety.
The ingredient’s actual regulatory disposition is still the missing entry. The documents in this collection stop short of that answer.
Is MOTS-c a supplement?
The cited record describes MOTS-c as research material, with no dietary-supplement status or FDA-approved finished drug. A laboratory-use description supplies no assurance that a particular preparation has the identity, strength or sterility required for human care.
The research review likewise leaves human safety and efficacy unestablished. Current compounding eligibility requires a current regulatory check by the professionals responsible for preparation. These archived entries cannot settle an individual legal or treatment decision.
Athlete eligibility
The safety context for MOTS-c includes prohibition in elite sport under the peptide and metabolic-modulator framework used by WADA and USADA. Athlete use can bring sanctions, including outside competition. A laboratory-use label does not remove that sporting restriction.
The animal dosage record and human blood findings answer different questions from regulatory eligibility. None of those entries establishes a treatment route.